Thousands of new lawsuits are expected to be filed against Novo Nordisk, the pharmaceutical company behind Ozempic, Rybelsus and Wegovy. The semaglutide medications, which are FDA approved treatments for type 2 diabetes, have become wildly popular in recent years for weight loss.
Ozempic lawsuits
Currently, approximately 1,500 lawsuits are pending in the multi-district litigation (MDL) involving Ozempic and other GLP-1 drugs, with hundreds more lawsuits being filed each month.
The federal judge in charge of the cases ordered the parties to produce experts on a variety of topics throughout 2025. For example, Plaintiffs must serve expert reports by July 16, 2025, after taking depositions and completing discovery on general causation topics related to gastroparesis. Summary judgment briefs will be filed by late 2025, with decisions by the court in early 2026. There are currently no jury trials set in the litigation.
Serious medical conditions linked to semaglutide medications
The lawsuits allege that Ozempic, along with other GLP-1 drugs, is responsible for causing a variety of serious medical conditions, including gastroparesis, an uncurable digestive disorder where the muscles in the stomach do not move as they should for food to be digested. Recent studies also link Ozempic, Rybelsus and Wegovy to vision loss. The condition, known as non-arteritic anterior ischemic optic neuropathy (NAION), occurs when blood flow to the optic nerve is blocked and causes sudden irreversible blindness.
Call us for a free case evaluation
If you or a loved one suffered injuries from Ozempic or other GLP-1 weight loss drugs, you may be entitled to financial compensation. To review your case, contact the lawyers at Alex Davis Law or call 502-882-6000 to schedule a free consultation today.